期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

贝尼地平及其在肾脏病治疗中的应用 被引量：1

原文传递
导出
摘要 钙拮抗剂是一类广泛应用于临床的降压药，根据药物核心分子结构和作用于L型钙通道亚单位的不同，分为二氢吡啶类和非二氢吡啶类两种类型。贝尼地平为长效二氢吡啶类钙拮抗剂，它除具有阻滞L型钙通道的作用外，还能阻滞T及N型钙通道，
作者 王艳艳 谌贻璞
机构地区 首都医科大学附属北京安贞医院肾内科
出处 《中华高血压杂志》 CAS CSCD 北大核心 2014年第5期415-417,共3页 Chinese Journal of Hypertension
关键词 贝尼地平 二氢吡啶类钙拮抗剂 应用 肾脏病 L型钙通道 治疗 N型钙通道 分子结构
分类号 R692 [医药卫生—泌尿科学]
  • 相关文献

参考文献21

  • 1张维忠.新型钙拮抗剂贝尼地平基础与临床研究进展[J].高血压杂志,2005,13(4):196-197. 被引量：34
  • 2Yao K, Nagashima K, Miki H. Pharmacological, pharmacokinet- ic, and clinical properties of benidipine hydroehloride, a novel, long-acting calcium channel blocker[J]. J Pharmacol Sci, 2006,100 (4) :243-261.
  • 3Tomino Y. Renoprotective effects of the L-/T-type calcium chan- nel blocker benidipine in patients with hypertension [J]. Curr Hypertens Rev,2013,9(2) :108-114.
  • 4Hayashi K, Wakino S, Sugano N, et al. Caz+ channel subtypes and pharmacology in the kidney[J]. Circ Res, 2007,100 (3) : 342- 353.
  • 5Richard S. Vascular effects of calcium channel antagonists new evidence[-J]. Drugs, 2005,65 Suppl 2 : 1-10.
  • 6谌贻璞.不同种类双氢吡啶钙通道阻滞剂的肾脏保护作用[J].北京医学,2009,31(3):178-180. 被引量：3
  • 7Nakamura T, Sato E, Fujiwara N, et al. Comparative effects of benidipine and amlodipine on proteinuria, urinary 8-OHdG, urina- ry L-FABP, and inflammatory and atherosclerosis markers in ear- ly-stage chronic kidney disease[J]. Am J Med Sci, 2010,339 (2): 157-163.
  • 8Morikawa T, Okumura M, Konishi Y, et al. Effects of benidipine on glomerular hemodynamies and proteinuria in patients with non- diabetic nephropathy[J]. Hypertens Res, 2002,25 (4) : 571-576.
  • 9Ohishi M, Takagi T, Ito N, et al. Renal-protective effect of T and L-type calcium channel blockers in hypertensive patients: an amlo- dipine-to-benidipine changeover (ABC) study[J]. Hypertens Res, 2007,30(9) : 797-806.
  • 10Tomino Y, Shimizu Y, Hamada C, et al. One-year results of an open-label study on antiproteinuric effect of benidipine in elderly patients with chronic kidney disease[J]. J Nephrol, 2011,24 (6) : 756-763.

二级参考文献14

  • 1Hayashi K,Wakino S,Sugano N,et al. Ca^2+ channel subtypes and pharmacology in the kidney. Circ Res, 2007, 100: 342- 353.
  • 2Hayashi K, Wakino S, Homma K, et al. Pathophysiologieal significance of T-type Ca^2+ channels: role of T-type Ca^2+ channels in renal mieroeireulation. J Pharmaeol Sci, 2005,99 : 221-227.
  • 3Richard S. Vascular effects of calcium channel antagonists: new evidence. Drugs, 2005,65 (Suppl 2) : 1-10.
  • 4Masumiya H, Tanaka Y, Tanaka H, et al. Inhibition of T- Type and L-Type Ca^2+ Currents by Aranidipine,a Novel Di hydropyridine Ca^2+ Antagonist. Pharmacology, 2000,61 : 57 61.
  • 5Moosmang S, Haider N, Bruderl B, et al. Antihypertensive effects of the putative T-type calcium channel antagonist mibefradil are mediated by the L-type calcium channel Ca vl. 2. Circ Res, 2006,98: 105-110.
  • 6Yue W, Kimura S, Fujisawa Y, et al. Benidipine dilates both pre-and post-glomerular arteriole in the canine kidney. Hypertens Res,2001,24 : 429-436.
  • 7Segura J, Garcia-Donaire JA, Ruilope LM, Are differences in calcium antagonists relevant across all stages of nephropathy or only proteinuric nephropathy? Curr Opin Nephrol Hypertens,2007,16 : 422-426.
  • 8Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA, 2001, 285:2719- 2728.
  • 9Baba S,J-MIND Study Group. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract,2001,54:191-201.
  • 10Inoue S, Tomino Y. Effects ol calcium antagonists in hypertensive patients with renal dysfunction: a prospective, randomized, parallel trial comparing benidipine and nifedipine. Nephrology (Carlton), 2004,9 :265-271.

共引文献34

同被引文献22

  • 1Hansen PB,Jensen BL,Andreasen D,et al. Differential expression of T-and L-type voltage-dependent calcium channels in renal resistance vessels. Circulation research,2001,89(7) :630-638.
  • 2Weir MR. The role of combination antihypertensive therapy in the prevention and treatment of chronic kidney disease. American journal of hypertension,2005 ,18(4 Pt 2) : 100-105.
  • 3Homma K,Hayashi K,Yamaguchi S,et al. Renal microcirculation and calcium channel subtypes. Current hypertension reviews, 2013,9(3):182-186.
  • 4Hayashi K,Wakino S,Sugano N,et al. Ca2+ channel subtypes and pharmacology in the kidney. Circulation research, 2007,100 (3): 342-353.
  • 5Hayashi K, Homma K’Wakino S,et al. T-type Ca channel blockade as a determinant of kidney protection. The Keio journal of medicine ,2010,59(3): 84-95.
  • 6Tomino Y. Renoprotective effects of the L-/T-type calcium channel blocker benidipine in patients with hypertension. Current hypertension reviews ,2013 ,9(2) ; 108-114.
  • 7Ertel EA, Campbell KP, Harpold MM,et al. Nomenclature of voltage-gated calcium channels. Neuron, 2000,25 (3) : 533-535.
  • 8Omae K,0gawa T,Nitta K. Influence of T—calcium channel blocker treatment on deterioration of renal function in chronic kidney disease. Heart and vessels, 2009,24 (4) : 301-307.
  • 9Saruta T, Hayashi K, Ogihara T,et al. Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease : subanalysis of the CASE-J Study. Hypertension research : official journal of the Japanese Society of Hypertension ,2009,32(6):505-512.
  • 10Arima S,Kohagura K,Xu HL,et al. Nongenomic vascular action of aldosterone in the glomerular microcirculation. Journal of the American Society of Nephrology : JASN, 2003 ,14(9) :2255-2263.

引证文献1

二级引证文献3

中华高血压杂志
2014年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部